Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes  Koen Van Besien,

Published byJohnathan Russell Modified over 6 years ago

Similar presentations

Presentation on theme: "Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes  Koen Van Besien,"— Presentation transcript:

1 Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes  Koen Van Besien, Rangesh Kunavakkam, Gaby Rondon, Marcos De Lima, Andrew Artz, Betul Oran, Sergio Giralt  Biology of Blood and Marrow Transplantation  Volume 15, Issue 5, Pages (May 2009) DOI: /j.bbmt Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

2 Figure 1 Survival. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

3 Figure 2 Progression-Free Survival.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

4 Figure 3 Acute GVHD. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

5 Figure 4 Chronic GVHD. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

6 Figure 5 Cumulative Probability of Treatment-Related Mortality.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

7 Figure 6 Cumulative probability of Disease Recurrence.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Download ppt "Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes  Koen Van Besien,"

Similar presentations

Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children  Daihong.

Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children  Daihong.
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction  Muzaffar H. Qazilbash, Ali Imran.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction  Muzaffar H. Qazilbash, Ali Imran.
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
CC-486 (Oral Azacitidine) Maintenance Therapy Is Well Tolerated after Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic.

CC-486 (Oral Azacitidine) Maintenance Therapy Is Well Tolerated after Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic.
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
Moderate Renal Function Impairment Does Not Affect Outcomes of Reduced-Intensity Conditioning with Fludarabine and Melphalan for Allogeneic Hematopoietic.

Moderate Renal Function Impairment Does Not Affect Outcomes of Reduced-Intensity Conditioning with Fludarabine and Melphalan for Allogeneic Hematopoietic.
Safety and Efficacy of Haploidentical Stem Cell Transplantation for Advanced Chronic Myeloid Leukemia  Kehinde Adekola, MD, Antonio di Stasi, MD, Roberto.

Safety and Efficacy of Haploidentical Stem Cell Transplantation for Advanced Chronic Myeloid Leukemia  Kehinde Adekola, MD, Antonio di Stasi, MD, Roberto.
Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations  Yachiyo.

Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations  Yachiyo.
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes 

Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes 
Long-Term Follow-Up of Patients Who Experienced Graft Failure Postallogeneic Progenitor Cell Transplantation. Results of a Single Institution Analysis 

Long-Term Follow-Up of Patients Who Experienced Graft Failure Postallogeneic Progenitor Cell Transplantation. Results of a Single Institution Analysis 
Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease
Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab  Marc Schnitzler, Jens Hasskarl,

Successful Treatment of Severe Acute Intestinal Graft-versus-Host Resistant to Systemic and Topical Steroids with Alemtuzumab  Marc Schnitzler, Jens Hasskarl,
Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia  Scott R. Solomon, Connie A. Sizemore, Xu Zhang,
Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years  Cynthia Huisman,
Low Incidence of Chronic GVHD after HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide in Older.

Low Incidence of Chronic GVHD after HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide in Older.
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation 

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation 
Musculoskeletal, Neurologic, and Cardiopulmonary Aspects of Physical Rehabilitation in Patients with Chronic Graft-versus-Host Disease  Sean Robinson.

Musculoskeletal, Neurologic, and Cardiopulmonary Aspects of Physical Rehabilitation in Patients with Chronic Graft-versus-Host Disease  Sean Robinson.
Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions  Darius Sairafi, Mats Remberger, Michael.

Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions  Darius Sairafi, Mats Remberger, Michael.

Similar presentations

Ads by Google